Dr. Sandor Schokker, MD, PhD

Research output

Research output per year 2014 2020 2021 2022 2022

• 10 Article
• 1 Review article
• 1 Phd-Thesis - Research and graduation internal

Research output per year

Research output per year

Search results

• 2022

  A phase Ib/II study of regorafenib and paclitaxel in patients with beyond first-line advanced esophagogastric carcinoma (REPEAT)

  Stroes, C. I., Schokker, S., Khurshed, M., van der Woude, S. O., Mathôt, R. A. A., Slingerland, M., de Vos-Geelen, J., Zucchetti, M., Matteo, C., van Dijk, E., Ylstra, B., Thijssen, V., Derks, S., Godefa, T., Dijksterhuis, W., Breimer, G. E., van Delden, O. M., Verhoeven, R. H. A., Meijer, S. L., Bijlsma, M. F., & 1 othersvan Laarhoven, H. W. M., 2022, In: Therapeutic advances in medical oncology. 14

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  3 Citations (Scopus)

• Circulating tumor DNA predicts outcome in metastatic gastroesophageal cancer

  van Velzen, M. J. M., Creemers, A., van den Ende, T., Schokker, S., Krausz, S., Reinten, R. J., Dijk, F., van Noesel, C. J. M., Halfwerk, H., Meijer, S. L., Mearadji, B., Derks, S., Bijlsma, M. F. & van Laarhoven, H. W. M., Sept 2022, In: Gastric cancer. 25, 5, p. 906-915 10 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  14 Citations (Scopus)
• 2021

  A phase ii study demonstrates no feasibility of adjuvant treatment with six cycles of s-1 and oxaliplatin in resectable esophageal adenocarcinoma, with ercc1 as biomarker for response to sox

  Stroes, C. I., Schokker, S., Molenaar, R. J., Mathôt, R. A. A., Bijlsma, M. F., van der Woude, S. O., Pereira, J. P. B., Hooijer, G. K. J., Verhoeven, R. H. A., Cats, A., Grootscholten, C., van Sandick, J. W., Creemers, G-J., Nieuwenhuijzen, G. A. P., Mohammad, N. H., Ruurda, J. P., Meijer, S. L., Hulshof, M. C. C. M., Henegouwen, M. I. V. B. & van Laarhoven, H. W. M., 1 Feb 2021, In: Cancers. 13, 4, p. 1-15 15 p., 839.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  3 Citations (Scopus)

• Neoadjuvant chemoradiotherapy combined with atezolizumab for resectable esophageal adenocarcinoma: A single-arm phase ii feasibility trial (PERFECT)

  Van Den Ende, T., De Clercq, N. C., Van Berge Henegouwen, M. I., Gisbertz, S. S., Geijsen, E. D., Verhoeven, R. H. A., Meijer, S. L., Schokker, S., Dings, M. P. G., Bergman, J. J. G. H. M., Mohammad, N. H., Ruurda, J. P., Van Hillegersberg, R., Mook, S., Nieuwdorp, M., De Gruijl, T. D., Soeratram, T. T. D., Ylstra, B., Van Grieken, N. C. T., Bijlsma, M. F., & 2 othersHulshof, M. C. C. M. & Van Laarhoven, H. W. M., Jun 2021, In: Clinical Cancer Research. 27, 12, p. 3351-3359 9 p.

  Research output: Contribution to journal › Article › Academic › peer-review
  128 Citations (Scopus)

• Towards novel systemic treatment approaches in esophagogastric cancer

  Schokker, S., 2021, 246 p.

  Research output: PhD Thesis › Phd-Thesis - Research and graduation internal

  Open Access
• 2020

  Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma

  Strijker, M., Soer, E. C., de Pastena, M., Creemers, A., Balduzzi, A., Beagan, J. J., Busch, O. R., van Delden, O. M., Halfwerk, H., van Hooft, J. E., van Lienden, K. P., Marchegiani, G., Meijer, S. L., van Noesel, C. J., Reinten, R. J., Roos, E., Schokker, S., Verheij, J., van de Vijver, M. J., Waasdorp, C., & 6 othersWilmink, J. W., Ylstra, B., Besselink, M. G., Bijlsma, M. F., Dijk, F. & van Laarhoven, H. W., 1 Mar 2020, In: International journal of cancer. 146, 5, p. 1445-1456 12 p.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  63 Citations (Scopus)

• Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab

  Schokker, S., Fusetti, F., Bonardi, F., Molenaar, R. J., Mathôt, R. A. A. & van Laarhoven, H. W. M., 1 Jan 2020, In: MABS. 12, 1, 1795492.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  10 Citations (Scopus)

• Phase II feasibility and biomarker study of neoadjuvant trastuzumab and pertuzumab with chemoradiotherapy for resectable human epidermal growth factor receptor 2-positive esophageal adenocarcinoma: Trap study

  Stroes, C. I., Schokker, S., Creemers, A., Molenaar, R. J., Hulshof, M. C. C. M., van der Woude, S. O., Bennink, R. J., Mathôt, R. A. A., Krishnadath, K. K., Punt, C. J. A., Verhoeven, R. H. A., van Oijen, M. G. H., Creemers, G. J., Nieuwenhuijzen, G. A. P., van der Sangen, M. J. C., Beerepoot, L. V., Heisterkamp, J., Los, M., Slingerland, M., Cats, A., & 5 othersHospers, G. A. P., Bijlsma, M. F., van Berge Henegouwen, M. I., Meijer, S. L. & van Laarhoven, H. W. M., 10 Feb 2020, In: Journal of clinical oncology. 38, 5, p. 462-471 10 p.

  Research output: Contribution to journal › Article › Academic › peer-review
  48 Citations (Scopus)

• Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis: systematic review and meta-analysis

  van Kleef, J. J., ter Veer, E., van den Boorn, H. C. G., Schokker, S., Ngai, L. L., Prins, M. J., Mohammad, N. H., van de Poll-Franse, L. V., Zwinderman, A. H., van Oijen, M. G. H., Sprangers, M. A. G. & van Laarhoven, H. W. M., 1 Jan 2020, In: Journal of the National Cancer Institute. 112, 1, p. 12-29 18 p.

  Research output: Contribution to journal › Article › Academic › peer-review
  36 Citations (Scopus)
• 2019

  Phase I Dose escalation study with expansion cohort of the addition of nab-paclitaxel to capecitabine and oxaliplatin (CapOx) as first-line treatment of metastatic esophagogastric adenocarcinoma (ACTION study)

  Schokker, S., van der Woude, S. O., van Kleef, J. J., van Zoen, D. J., van Oijen, M. G. H., Mearadji, B., Beenen, L. F. M., Stroes, C. I., Waasdorp, C., Jibodh, R. A., Creemers, A., Meijer, S. L., Punt, C. J. A., Bijlsma, M. F. & van Laarhoven, H. W. M., 1 Jun 2019, In: Cancers. 11, 6, 827.

  Research output: Contribution to journal › Article › Academic › peer-review

  Open Access
  4 Citations (Scopus)
• 2018

  Prognostic and predictive factors for overall survival in metastatic oesophagogastric cancer: A systematic review and meta-analysis

  ter Veer, E., van Kleef, J. J., Schokker, S., van der Woude, S. O., Laarman, M., Haj Mohammad, N., Sprangers, M. A. G., van Oijen, M. G. H. & van Laarhoven, H. W. M., 2018, In: European journal of cancer (Oxford, England. 103, p. 214-226

  Research output: Contribution to journal › Review article › Academic › peer-review

  Open Access
  26 Citations (Scopus)
• 2014

  Survival differences in pediatric pulmonary arterial hypertension: clues to a better understanding of outcome and optimal treatment strategies

  Zijlstra, W. M. H., Douwes, J. M., Rosenzweig, E. B., Schokker, S., Krishnan, U., Roofthooft, M. T. R., Miller-Reed, K., Hillege, H. L., Ivy, D. D. & Berger, R. M. F., 2014, In: Journal of the American College of Cardiology. 63, 20, p. 2159-2169

  Research output: Contribution to journal › Article › Academic › peer-review
  118 Citations (Scopus)